DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Indoximod is an investigational drug.
There have been 14 clinical trials for Indoximod. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2017.
The most common disease conditions in clinical trials are Glioma, Glioblastoma, and Brain Neoplasms. The leading clinical trial sponsors are NewLink Genetics Corporation, National Cancer Institute (NCI), and Theodore S. Johnson.
There are fifty-seven US patents protecting this investigational drug and four hundred and eighty-one international patents.
Recent Clinical Trials for Indoximod
|Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG||Emory University||Phase 2|
|Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG||Theodore S. Johnson||Phase 2|
|A 2-part, Phase 1, Randomized Study in Health Men to: 1) Evaluate the Pharmacokinetics and Safety of Different Doses Indoximod HCL (Salt) Tablets and; 2) Compare the Proportion of 2 Different Formulations of Indoximod That Enters the Circulation and||NewLink Genetics Corporation||Early Phase 1|
Top disease conditions for Indoximod
Top clinical trial sponsors for Indoximod
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Indoximod||Start Trial||Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus||Seattle Genetics, Inc. (Bothell, WA)||Start Trial|
|Indoximod||Start Trial||Antibodies to ICOS||Jounce Therapeutics, Inc. (Cambridge, MA)||Start Trial|
|Indoximod||Start Trial||Tank-binding kinase inhibitor compounds||Gilead Sciences, Inc. (Foster City, CA)||Start Trial|
|Indoximod||Start Trial||COX-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers||REILEY PHARMACEUTICALS, INC. (San Jose, CA)||Start Trial|
|Indoximod||Start Trial||Carbidopa for the treatment of cancer||Texas Tech University System (Lubbock, TX)||Start Trial|
|Indoximod||Start Trial||Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy||CITY OF HOPE (Duarte, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Indoximod||European Patent Office||1917020||2025-07-07||Start Trial|
|Indoximod||European Patent Office||2722051||2025-07-07||Start Trial|
|Indoximod||European Patent Office||3498289||2025-07-07||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|